Epigenetic and genetic alterations of PTEN in hepatocellular carcinoma
- PMID: 17441812
- DOI: 10.1111/j.1872-034X.2007.00042.x
Epigenetic and genetic alterations of PTEN in hepatocellular carcinoma
Abstract
Aim: To investigate the roles of epigenetic and genetic alterations of the phosphatase and tensin homologue on chromosome 10 gene (PTEN) in carcinogenesis and the development of hepatocellular carcinomas (HCC).
Methods: A total of 56 cases of HCC tissues and six liver cell lines were studied for the expression of PTEN by immunohistochemistry and Western blot analysis. The PTEN gene mutations in exon5 and exon8 were detected by a combination of single-strand conformation polymorphism (SSCP) analysis and DNA sequencing. Methylation-specific PCR (MSP) was used to identify PTEN promoter methylation.
Results: Of the 56 cases of HCC, 24 (42.9%) expressed the PTEN protein. All surrounding liver tissues of the hepatoma (32 cases) were positive for PTEN. Of the six cell lines, three liver cancer cell lines showed a low expression of PTEN. Five mutations of 56 HCC samples were detected. All of them were located at intron4. No mutation was found in exon5 and exon8. After MSP analysis, we found nine cases of PTEN promoter methylation in 56 specimens (16.1%). However, no CpG island of PTEN was found to be methylated in all six liver cell lines.
Conclusion: The level of PTEN protein was altered in part of the HCC. The downregulation of PTEN expression may not be mainly associated with the PTEN mutations, but partly due to PTEN promoter methylation and other epigenetic regulation.
Similar articles
-
Methylation status of the PTEN gene in adenoid cystic carcinoma cells.Mol Med Rep. 2010 Sep-Oct;3(5):775-9. doi: 10.3892/mmr.2010.337. Epub 2010 Jul 26. Mol Med Rep. 2010. PMID: 21472313
-
Down-regulation of PTEN expression due to loss of promoter activity in human hepatocellular carcinoma cell lines.World J Gastroenterol. 2005 Aug 7;11(29):4472-7. doi: 10.3748/wjg.v11.i29.4472. World J Gastroenterol. 2005. PMID: 16052674 Free PMC article.
-
PTEN mutation, methylation and expression in breast cancer patients.Oncol Lett. 2013 Jul;6(1):161-168. doi: 10.3892/ol.2013.1331. Epub 2013 May 8. Oncol Lett. 2013. PMID: 23946797 Free PMC article.
-
[Expression of phosphatase and tensin homology deleted on chromosome ten(PTEN) and p53 protein and their significance in human hepatocellular carcinomas].Ai Zheng. 2003 Jan;22(1):42-5. Ai Zheng. 2003. PMID: 12561434 Chinese.
-
[BORIS Regulates SOCS3 Expression Through Epigenetic Mechanisms in Human Hepatocellular Carcinoma Cells].Sichuan Da Xue Xue Bao Yi Xue Ban. 2018 Jan;49(1):1-7. Sichuan Da Xue Xue Bao Yi Xue Ban. 2018. PMID: 29737080 Chinese.
Cited by
-
Transformation of SOX9+ cells by Pten deletion synergizes with steatotic liver injury to drive development of hepatocellular and cholangiocarcinoma.Sci Rep. 2021 Jun 3;11(1):11823. doi: 10.1038/s41598-021-90958-1. Sci Rep. 2021. PMID: 34083580 Free PMC article.
-
Ectopic NGAL expression can alter sensitivity of breast cancer cells to EGFR, Bcl-2, CaM-K inhibitors and the plant natural product berberine.Cell Cycle. 2012 Dec 1;11(23):4447-61. doi: 10.4161/cc.22786. Epub 2012 Nov 16. Cell Cycle. 2012. PMID: 23159854 Free PMC article.
-
PTEN in liver diseases and cancer.World J Gastroenterol. 2010 Oct 7;16(37):4627-33. doi: 10.3748/wjg.v16.i37.4627. World J Gastroenterol. 2010. PMID: 20872961 Free PMC article.
-
PTEN mutation spectrum in breast cancers and breast hyperplasia.J Cancer Res Clin Oncol. 2010 Sep;136(9):1303-11. doi: 10.1007/s00432-010-0781-3. Epub 2010 Mar 19. J Cancer Res Clin Oncol. 2010. PMID: 20300775
-
Pharmacogenetics of hepatocellular carcinoma and cholangiocarcinoma.Cancer Drug Resist. 2019 Sep 19;2(3):680-709. doi: 10.20517/cdr.2019.006. eCollection 2019. Cancer Drug Resist. 2019. PMID: 35582588 Free PMC article. Review.
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous
